

# UBS Group AG (consolidated) BIS Basel III leverage ratio information

Second quarter 2016

This document provides BIS Basel III leverage ratio information as of 30 June 2016, as required by the revised FINMA Circular 2008 / 22 "Disclosure – banks."

- Refer to our **second quarter 2016 report for information on our Swiss SRB leverage ratio as of 30 June 2016**
- Refer to **"Basel III Pillar 3 First Half 2016 Report,"** which will be available from **17 August 2016** under **"Pillar 3, SEC filings & other disclosures"** at [www.ubs.com/investors](http://www.ubs.com/investors) for more information
- Refer to the **"UBS Group AG consolidated supplemental disclosures required under Basel III Pillar 3 regulations"** in the **"Additional regulatory information"** section of our **Annual Report 2015** for more information

## BIS Basel III leverage ratio disclosure requirements

The tables in the following section provide BIS leverage ratio information according to the current disclosure requirements.

The BIS leverage ratio is calculated by dividing the period-end tier 1 capital by the period-end leverage ratio denominator (LRD). The LRD consists of IFRS on-balance sheet assets and off-balance sheet items. Derivative exposures are adjusted for a number of items, including replacement value and eligible cash variation margin netting, the current exposure method add-on and net notional amounts for written credit derivatives. The LRD further includes an additional charge for counterparty credit risk related to securities financing transactions. In addition, balance sheet assets deducted from our tier 1 capital are excluded from LRD, resulting in a difference between phase-in and fully applied LRD for DTAs and net defined benefit pension plan assets.

The table "Reconciliation of IFRS total assets to BIS Basel III total on-balance sheet exposures excluding derivatives and securities financing transactions" below shows the difference between total IFRS assets per IFRS consolidation scope and the BIS total on-balance sheet exposures, which are the starting point for calculating the BIS LRD as shown in the "BIS Basel III leverage ratio common disclosure" table on the next page. The difference is due to the application of the regulatory scope of

consolidation for the purpose of the BIS calculation. In addition, carrying values for derivative financial instruments and securities financing transactions are deducted from IFRS total assets. They are measured differently under BIS leverage ratio rules and are therefore added back in separate exposure line items in the "BIS Basel III leverage ratio common disclosure" table on the next page.

- Refer to our second quarter 2016 report for information on our Swiss SRB leverage ratio as of 30 June 2016
- Refer to the "UBS Group AG consolidated supplemental disclosures required under Basel III Pillar 3 regulations" in the "Additional regulatory information" section of our Annual Report 2015 for more information on the regulatory scope of consolidation

## BIS Basel III leverage ratio

As of 30 June 2016, our BIS Basel III leverage ratio was 4.2% on a fully applied basis and 4.8% on a phase-in basis. The BIS Basel III LRD was CHF 898 billion on a fully applied basis and CHF 902 billion on a phase-in basis.

- Refer to our second quarter 2016 report for information on our BIS Basel III leverage ratio movements

## Reconciliation of IFRS total assets to BIS Basel III total on-balance sheet exposures excluding derivatives and securities financing transactions

| <i>CHF million</i>  | <b>30.6.16</b> |
|---|----------------|
| <b>On-balance sheet exposures</b>   |                |
| IFRS total assets   | 989,397        |
| Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for accounting purposes but outside the scope of regulatory consolidation              | (15,154)       |
| Adjustment for investments in banking, financial, insurance or commercial entities that are outside the scope of consolidation for accounting purposes but consolidated for regulatory purposes | 0              |
| Adjustment for fiduciary assets recognized on the balance sheet pursuant to the operative accounting framework but excluded from the leverage ratio exposure measure                            | 0              |
| Less carrying value of derivative financial instruments in IFRS total assets <sup>1</sup>   | (228,420)      |
| Less carrying value of securities financing transactions in IFRS total assets <sup>2</sup>  | (119,310)      |
| Adjustments to accounting values  | 0              |
| <b>On-balance sheet items excluding derivatives and securities financing transactions, but including collateral</b>   | <b>626,513</b> |
| Asset amounts deducted in determining BIS Basel III tier 1 capital  | (12,873)       |
| <b>Total on-balance sheet exposures (excluding derivatives and securities financing transactions)</b>   | <b>613,640</b> |

<sup>1</sup> Consists of positive replacement values and cash collateral receivables on derivative instruments in accordance with the regulatory scope of consolidation. <sup>2</sup> Consists of cash collateral on securities borrowed, reverse repurchase agreements, margin loans and prime brokerage receivables related to securities financing transactions in accordance with the regulatory scope of consolidation.

The naming convention in the following table is based on BIS guidance and does not reflect UBS naming conventions.

## BIS Basel III leverage ratio common disclosure

| <i>CHF million, except where indicated</i>  |  | <b>30.6.16</b> |
|---|--|----------------|
| <b>On-balance sheet exposures</b>   |  |                |
| 1   | On-balance sheet items excluding derivatives and SFTs <sup>1</sup> , but including collateral  | 626,513        |
| 2   | (Asset amounts deducted in determining Basel III tier 1 capital)   | (12,873)       |
| <b>3</b>  | <b>Total on-balance sheet exposures (excluding derivatives and SFTs<sup>1</sup>)</b>   | <b>613,640</b> |
| <b>Derivative exposures</b>   |  |                |
| 4   | Replacement cost associated with all derivatives transactions (i.e., net of eligible cash variation margin)                              | 61,822         |
| 5   | Add-on amounts for PFE <sup>2</sup> associated with all derivatives transactions   | 87,572         |
| 6   | Gross-up for derivatives collateral provided where deducted from the balance sheet assets pursuant to the operative accounting framework | 0              |
| 7   | (Deductions of receivables assets for cash variation margin provided in derivatives transactions)  | (17,088)       |
| 8   | (Exempted CCP <sup>3</sup> leg of client-cleared trade exposures)  | (15,286)       |
| 9   | Adjusted effective notional amount of all written credit derivatives <sup>4</sup>  | 144,907        |
| 10  | (Adjusted effective notional offsets and add-on deductions for written credit derivatives) <sup>5</sup>                                  | (140,714)      |
| <b>11</b>   | <b>Total derivative exposures</b>  | <b>121,213</b> |
| <b>Securities financing transaction exposures</b>   |  |                |
| 12  | Gross SFT <sup>1</sup> assets (with no recognition of netting), after adjusting for sale accounting transactions                         | 171,837        |
| 13  | (Netted amounts of cash payables and cash receivables of gross SFT <sup>1</sup> assets)  | (52,528)       |
| 14  | CCR <sup>6</sup> exposure for SFT <sup>1</sup> assets  | 10,433         |
| 15  | Agent transaction exposures  | 0              |
| <b>16</b>   | <b>Total securities financing transaction exposures</b>  | <b>129,742</b> |
| <b>Other off-balance sheet exposures</b>  |  |                |
| 17  | Off-balance sheet exposure at gross notional amount  | 105,954        |
| 18  | (Adjustments for conversion to credit equivalent amounts)  | (68,119)       |
| <b>19</b>   | <b>Total off-balance sheet items</b>   | <b>37,836</b>  |
| <b>Total exposures (leverage ratio denominator), phase-in</b>                             |  | <b>902,431</b> |
| (Additional asset amounts deducted in determining Basel III tier 1 capital fully applied) |  | (4,236)        |
| <b>Total exposures (leverage ratio denominator), fully applied</b>                        |  | <b>898,195</b> |
| <b>Capital and total exposures (leverage ratio denominator), phase-in</b>                 |  |                |
| 20  | Tier 1 capital   | 42,934         |
| 21  | Total exposures (leverage ratio denominator)   | 902,431        |
| <b>Leverage ratio</b>   |  |                |
| <b>22</b>   | <b>Basel III leverage ratio phase-in (%)</b>   | <b>4.8</b>     |
| <b>Capital and total exposures (leverage ratio denominator), fully applied</b>            |  |                |
| 20  | Tier 1 capital   | 38,049         |
| 21  | Total exposures (leverage ratio denominator)   | 898,195        |
| <b>Leverage ratio</b>   |  |                |
| <b>22</b>   | <b>Basel III leverage ratio fully applied (%)</b>  | <b>4.2</b>     |

<sup>1</sup> Securities financing transactions. <sup>2</sup> Potential future exposure – Current exposure method (CEM add-on) based on notional amounts. <sup>3</sup> Central cleared counterparties. <sup>4</sup> Includes protection sold including agency transactions. <sup>5</sup> Protection sold can be offset with protection bought on the same underlying reference entity provided the conditions according to the Basel III leverage ratio framework and disclosure requirements are met. <sup>6</sup> Counterparty credit risk.

The naming convention in the following table is based on BIS guidance and does not reflect UBS naming conventions.

### BIS Basel III leverage ratio summary comparison

| <i>CHF million</i> |   | <b>30.6.16</b> |
|--------------------|---|----------------|
| 1                  | Total consolidated assets as per published financial statements   | 989,397        |
| 2                  | Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for accounting purposes but outside the scope of regulatory consolidation <sup>1</sup> | (28,028)       |
| 3                  | Adjustment for fiduciary assets recognised on the balance sheet pursuant to the operative accounting framework but excluded from the leverage ratio exposure measure                            | 0              |
| 4                  | Adjustments for derivative financial instruments  | (107,207)      |
| 5                  | Adjustment for securities financing transactions (i.e., repos and similar secured lending)  | 10,433         |
| 6                  | Adjustment for off-balance sheet items (i.e., conversion to credit equivalent amounts of off-balance sheet exposures)   | 37,836         |
| 7                  | Other adjustments   | 0              |
| <b>8</b>           | <b>Leverage ratio exposure (leverage ratio denominator), phase-in</b>   | <b>902,431</b> |

<sup>1</sup> This item includes assets that are deducted from tier 1 capital.

### BIS Basel III leverage ratio

*CHF million, except where indicated*

| <b>Phase-in</b>                                  | <b>30.6.16</b> | 31.3.16 | 31.12.15 | 30.9.15 |
|--|----------------|---------|----------|---------|
| Total tier 1 capital                             | <b>42,934</b>  | 43,541  | 44,559   | 44,125  |
| BIS total exposures (leverage ratio denominator) | <b>902,431</b> | 910,000 | 904,014  | 941,216 |
| BIS Basel III leverage ratio (%)                 | <b>4.8</b>     | 4.8     | 4.9      | 4.7     |
| <b>Fully applied</b>                             | <b>30.6.16</b> | 31.3.16 | 31.12.15 | 30.9.15 |
| Total tier 1 capital                             | <b>38,049</b>  | 37,438  | 36,198   | 36,526  |
| BIS total exposures (leverage ratio denominator) | <b>898,195</b> | 905,801 | 897,607  | 935,536 |
| BIS Basel III leverage ratio (%)                 | <b>4.2</b>     | 4.1     | 4.0      | 3.9     |

---

**Notice to investors** | This document and the information contained herein are provided solely for information purposes, and are not to be construed as solicitation of an offer to buy or sell any securities or other financial instruments in Switzerland, the United States or any other jurisdiction. No investment decision relating to securities of or relating to UBS Group AG, UBS AG or their affiliates should be made on the basis of this document. Refer to UBS's second quarter 2016 report and its Annual Report 2015 for additional information. These reports are available at [www.ubs.com/investors](http://www.ubs.com/investors).

**Rounding** | Numbers presented throughout this document may not add up precisely to the totals provided in the tables and text. Percentages, percent changes and absolute variances are calculated on the basis of rounded figures displayed in the tables and text and may not precisely reflect the percentages, percent changes and absolute variances that would be derived based on figures that are not rounded.

**Tables** | Within tables, blank fields generally indicate that the field is not applicable or not meaningful, or that information is not available as of the relevant date or for the relevant period. Zero values generally indicate that the respective figure is zero on an actual or rounded basis. Percentage changes are presented as a mathematical calculation of the change between periods.